Head-To-Head Analysis: Apellis Pharmaceuticals (APLS) vs. Its Rivals

Apellis Pharmaceuticals (NASDAQ: APLS) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it contrast to its rivals? We will compare Apellis Pharmaceuticals to related companies based on the strength of its institutional ownership, dividends, risk, analyst recommendations, earnings, profitability and valuation.

Valuation and Earnings

This table compares Apellis Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Apellis Pharmaceuticals N/A -$27.12 million -19.06
Apellis Pharmaceuticals Competitors $631.32 million $62.30 million 74.29

Apellis Pharmaceuticals’ rivals have higher revenue and earnings than Apellis Pharmaceuticals. Apellis Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of recent ratings and target prices for Apellis Pharmaceuticals and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Apellis Pharmaceuticals 0 0 4 0 3.00
Apellis Pharmaceuticals Competitors 174 845 1855 61 2.61

Apellis Pharmaceuticals presently has a consensus target price of $27.00, indicating a potential upside of 77.05%. As a group, “Biopharmaceuticals” companies have a potential upside of 3.34%. Given Apellis Pharmaceuticals’ stronger consensus rating and higher possible upside, equities analysts clearly believe Apellis Pharmaceuticals is more favorable than its rivals.


This table compares Apellis Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Apellis Pharmaceuticals N/A N/A -324.78%
Apellis Pharmaceuticals Competitors -13,491.55% -54.46% -24.94%

Institutional & Insider Ownership

11.9% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


Apellis Pharmaceuticals rivals beat Apellis Pharmaceuticals on 7 of the 12 factors compared.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.

Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply